Best Low Price Stocks To Buy Right Now

Protect American jobs by getting tough on China.

That’s the underlying idea behind President-elect Donald Trump’s threat of a 45% tariff against China as a ploy to bring jobs back to America.

Before pursuing that strategy, however, Trump might want to check out what happened when his predecessor tried that.

President Obama slapped a stiff 35% tariff on Chinese tires in 2009 after American companies complained about unfair competition. They said China was flooding America with tires at low prices making it tough for U.S. companies to compete. The tire tariff gradually waned, and finally ended in 2012.

The tariff saved 1,200 U.S. tire jobs, which had been in sharp decline. And U.S. tire production rose after a major decline.

“Over a thousand Americans are working today because we stopped a surge in Chinese tires,” Obama said in his 2012 State of the Union address.

But a study from the Peterson Institute of International Economics found that the tariffs cost Americans in many other ways.

Best Low Price Stocks To Buy Right Now: GTT Communications, Inc.(GTT)

Advisors’ Opinion:

  • [By ]

    In the Lightning Round, Cramer was bullish on GTT Communications (GTT) , Steel Dynamics (STLD) , Nucor (NUE) , Marriott International (MAR) , MGM Resorts (MGM) and Twitter (TWTR) .

  • [By ]

    GTT Communications (GTT) : “I think they have a great business model. I say buy, buy, buy.”

    Steel Dynamics (STLD) : “That’s a great steel company and the only one I’ll recommend other than Nucor (NUE) .”

  • [By Lisa Levin]

    Analysts at KeyBanc upgraded GTT Communications, Inc. (NYSE: GTT) from Sector Weight to Overweight.

    GTT Communications shares fell 0.64 percent to $46.35 in pre-market trading.

Best Low Price Stocks To Buy Right Now: Energy Select Sector SPDR ETF (XLE)

Advisors’ Opinion:

  • [By ]

    When we compare the energy sectors recent run to the S&P 500, its not even close. The Energy Select Sector SPDR (NYSE:XLE) has jumped more than 20% since Sept. 1. The S&P is up a little more than 10% over the same timeframe.

  • [By ]

    Life in the oil industry has been tough since the price of crude oil fell from north of $100 per barrel in 2014 to less than $40 per barrel by the end of 2015. Many small oil exploration and production companies went belly up since they couldn’t turn a profit with such low oil prices. The effects rippled throughout the entire energy sector. As you can see in the chart below, the Energy Select Sector SPDR ETF (NYSE: XLE) tumbled 45% from its 2014 highs to its 2016 lows:

  • [By Ethan Ryder]

    Traders sold shares of Energy Select Sector SPDR Fund (NYSEARCA:XLE) on strength during trading hours on Thursday. $150.97 million flowed into the stock on the tick-up and $236.14 million flowed out of the stock on the tick-down, for a money net flow of $85.17 million out of the stock. Of all stocks tracked, Energy Select Sector SPDR Fund had the 0th highest net out-flow for the day. Energy Select Sector SPDR Fund traded up $0.09 for the day and closed at $73.65

  • [By Todd Shriber, ETF Professor]

    The energy sector has been on a tear in the second quarter. The Energy Select Sector SPDR (NYSE: XLE), the largest energy exchange-traded fund by assets, is higher by 17 percent so far in the quarter while the S&P 500 is about 5.3 percent.

  • [By ]

    When we compare the energy sectors recent run to the S&P 500, its not even close. The Energy Select Sector SPDR (NYSE:XLE) has jumped more than 25% since Sept. 1. The S&P is up a 15% over the same timeframe.

  • [By Jim Crumly]

    Crude oil surged over $70 a barrel after the announcement that the U.S. will exit the Iran nuclear deal. TheEnergy Select Sector SPDR ETF (NYSEMKT:XLE) jumped 2%. Interest on 10-year Treasurys broke through the 3% level, boosting financial shares, with theFinancial Select Sector SPDR ETF (NYSEMKT:XLF) closing up 1.5%.

Best Low Price Stocks To Buy Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) decreased to 3.45 million shares from the previous 3.50 million. The stock recently traded at $274.50, within a 52-week range of $244.28 to $370.57.

  • [By Chris Lange]

    Ionis Pharmaceuticals Inc. (NASDAQ: IONS) shares made a handy gain on Friday after the firm announced an expanded strategic collaboration with Biogen Inc. (NASDAQ: BIIB). Through this partnership, these companies are planning to tackle and develop novel antisense drug candidates for a broad range of neurological diseases.

  • [By Brian Orelli]

    Drug-developer Biogen (NASDAQ:BIIB) reported a pretty strong earningsincrease in the first quarter. While revenue growth wasn’t as solid, investors appear to be giving management a pass, thanks to its explanations on why slowing first-quarter sales aren’t a sign of future trouble.

  • [By Brian Orelli]

    Data source: Ionis Pharmaceuticals.

    What happened with Ionis Pharmaceuticals this quarter?
    Revenue increased thanks to $41 million in royalties from Biogen’s (NASDAQ:BIIB) sales of Spinraza, up from just $5 million in the year-ago quarter. Because the tiered royalty rates reset each year, the royalties as a percentage of sales will end up being higher in the quarters to come this year. Despite the higher revenue, earnings turned negative on a GAAP (generally accepted accounting principles) basis: Ionis and Akcea Therapeutics (NASDAQ:AKCA) increased spending in preparation for the launch of Tegsedi for hereditary transthyretin amyloidosis (hATTR), and Waylivra for familial chylomicronemia syndrome, a rare disease that causes the buildup of lipids. Ionis is still the majority owner of Akcea, so its financials are incorporated into Ionis’ financials. The Food and Drug Administration pushed back its goal for making a decision on the marketing application for Tegsedi (the new brand name for inotersen) to Oct. 6, 2018. Ionis provided additional data analysis that the FDA needs additional time to review. In April, Ionis signed another deal with Biogen to develop antisense drugs for neurological disorders. In the deal, Ionis gets $1 billion up front, including an equity investment, in exchange for Biogen having first choice of neurology targets on which to exclusively collaborate with Ionis. Biogen is paying for everything beyond the initial discovery stage, with Ionis eligible for royalties and milestone payments as the drugs advance.

    Image source: Getty Images.

Leave a Reply

Your email address will not be published. Required fields are marked *